Supreme Court weighs liability shield for generic drug makers
The Supreme Court will soon rule on generic drug manufacturers’ liability for pharmacist prescribing decisions.
Why it matters: The decision could reshape pharmaceutical liability law, directly impacting legal risk management for drug makers and pharmacies. It may also alter the balance between affordable access to generics and protection of brand-name patent rights.
- The case involves Amarin Pharma and Hikma Pharmaceuticals over generic promotion of patented uses.
- At stake is whether generics can be held liable for promoting drugs for indications still under patent protection.
- Generic drugs represent around 90% of the U.S. prescription drug market.
- The ruling could directly affect how marketing practices are scrutinized and regulated.
The U.S. Supreme Court is set to deliver a significant decision in the case involving Amarin Pharma and Hikma Pharmaceuticals. At issue is whether generic drug makers can be held liable if pharmacists prescribe their products for uses still protected by brand-name patents.
The case centers on Hikma's generic version of Amarin’s heart drug Vascepa and the extent of liability arising from promoting drugs for patent-protected indications. Legal observers say this dispute could alter the balance between advancing affordable generics and safeguarding intellectual property rights as courts interpret marketing practices.
- "The whole case is over affordability of prescription medicine," said John Murphy, CEO of the Association for Accessible Medicines.
- Rothwell Figg, a legal analysis firm, notes: "The decision will reset the balance of generic competition and patent protection and how courts will interpret that balance in an era where drug marketing is under increased scrutiny."
The Supreme Court’s ruling will clarify the boundaries of induced patent infringement liability for generic manufacturers, which could shape future risk management strategies in the industry according to legal analysis.
Generic drugs account for roughly 90% of U.S. prescriptions, generating major cost savings for the healthcare system and consumers. The Court’s decision on this patent and liability question will be closely watched across the pharmaceutical sector.
By the numbers:
- 90% — share of U.S. prescription drug market filled by generics
- $1.67 trillion — savings to the U.S. healthcare system over a recent decade from generic substitution
- 80%+ — typical drop in prices after generic entry